COMMUNIQUÉS West-GlobeNewswire

JenaValve Appoints Tonya Porter as Vice President of Regulatory Affairs
20/05/2026
IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy® Transcatheter Heart Valve (THV) System, today announced the appointment of Tonya Porter as Vice [...]
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
20/05/2026
Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use. In a separate study, patients receiving monthly [...]
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
20/05/2026
BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that [...]
Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors
20/05/2026
Next-generation multispecific antibody, ISB 2301, targets 3 tumor-associated antigens (TAAs) and activates both T cells and natural killer (NK) cells IGI’s clinically validated BEAT ® platform enabled the development of [...]
Aeroflow Urology Donates to National Diaper Bank Network and United Way to Improve National Health Equity
20/05/2026
Gifts to both organizations reflect Aeroflow Urology’s continuous commitment to community partnerships that directly support underserved families ASHEVILLE, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Aeroflow Urology , a [...]
Syndax Announces Participation in Upcoming Investor Conferences
20/05/2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief [...]
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
20/05/2026
MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
20/05/2026
PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment [...]
Stablecoin Development Corporation Reports First Quarter 2026 Financial Results
20/05/2026
Company Generated $22.3 Million of Operating Income and Reported $552.4 Million of GAAP Net Income, Including Significant Non-Cash Warrant-Related Gains Company Held Approximately 2.15 Billion SKY Tokens at March 31, [...]
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
20/05/2026
- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals – - SAC awards require intensive product and value analysis vetting by a surgical committee and streamline the [...]
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
20/05/2026
REDWOOD CITY, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Codexis, a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, shared new advances in RNA [...]
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
20/05/2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases [...]
23andMe Partners with HealthEx to Connect Medical Records with Your DNA for the Future of Personalized Medicine
20/05/2026
23andMe’s new AI Health Summary Turns Genetics, Medical Records, Labs, and Lifestyle Data Into Personalized, Evidence-Based Recommendations PALO ALTO, Calif. and SAN FRANCISCO, May 20, 2026 (GLOBE NEWSWIRE) -- 23andMe [...]
IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
20/05/2026
ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive [...]
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
20/05/2026
Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra ® (resmetirom) Analysis of two-year data in patients with [...]
Sustainability Leader Ashley McKeon Selected as Soil Health Institute’s President and CEO
20/05/2026
MORRISVILLE, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Ashley McKeon, a seasoned agriculture and sustainability executive, will lead the Soil Health Institute (SHI) into its next decade. McKeon, who previously led [...]
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
20/05/2026
Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Segment also discusses evolving treatment landscape, immunologically “cold” tumors [...]
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
20/05/2026
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will [...]
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
20/05/2026
TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“ PharmAla ” or the “ Company ”), a global leader in the research, development, and manufacturing of novel MDXX-class [...]

Pages